These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27430283)

  • 1. mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review).
    Hu K; Dai HB; Qiu ZL
    Oncol Rep; 2016 Sep; 36(3):1219-25. PubMed ID: 27430283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR: An attractive therapeutic target for osteosarcoma?
    Ding L; Congwei L; Bei Q; Tao Y; Ruiguo W; Heze Y; Bo D; Zhihong L
    Oncotarget; 2016 Aug; 7(31):50805-50813. PubMed ID: 27177330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
    Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
    IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.
    Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q
    Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells].
    Liu PY; Zhang WB; Wang J; Shen YH; Wei YY
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
    Qiu Q; Jiang J; Lin L; Cheng S; Xin D; Jiang W; Shen J; Hu Z
    Int J Oncol; 2016 Jun; 48(6):2508-20. PubMed ID: 27082640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Id-1 promotes osteosarcoma cell growth and inhibits cell apoptosis via PI3K/AKT signaling pathway.
    Hao L; Liao Q; Tang Q; Deng H; Chen L
    Biochem Biophys Res Commun; 2016 Feb; 470(3):643-649. PubMed ID: 26797271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis.
    Zhou Q; Deng Z; Zhu Y; Long H; Zhang S; Zhao J
    Med Oncol; 2010 Dec; 27(4):1239-45. PubMed ID: 19936974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
    Perry JA; Kiezun A; Tonzi P; Van Allen EM; Carter SL; Baca SC; Cowley GS; Bhatt AS; Rheinbay E; Pedamallu CS; Helman E; Taylor-Weiner A; McKenna A; DeLuca DS; Lawrence MS; Ambrogio L; Sougnez C; Sivachenko A; Walensky LD; Wagle N; Mora J; de Torres C; Lavarino C; Dos Santos Aguiar S; Yunes JA; Brandalise SR; Mercado-Celis GE; Melendez-Zajgla J; Cárdenas-Cardós R; Velasco-Hidalgo L; Roberts CW; Garraway LA; Rodriguez-Galindo C; Gabriel SB; Lander ES; Golub TR; Orkin SH; Getz G; Janeway KA
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):E5564-73. PubMed ID: 25512523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/Akt signaling in osteosarcoma.
    Zhang J; Yu XH; Yan YG; Wang C; Wang WJ
    Clin Chim Acta; 2015 Apr; 444():182-92. PubMed ID: 25704303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
    Zhou R; Zhang Z; Zhao L; Jia C; Xu S; Mai Q; Lu M; Huang M; Wang L; Wang X; Jin D; Bai X
    J Orthop Res; 2011 Jun; 29(6):846-52. PubMed ID: 21246613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p.
    Song H; Liu J; Wu X; Zhou Y; Chen X; Chen J; Deng K; Mao C; Huang S; Liu Z
    Aging (Albany NY); 2019 Nov; 11(21):9794-9810. PubMed ID: 31724536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
    Long XH; Zhang GM; Peng AF; Luo QF; Zhang L; Wen HC; Zhou RP; Gao S; Zhou Y; Liu ZL
    Oncol Rep; 2014 Jan; 31(1):328-34. PubMed ID: 24172910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
    Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
    Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
    Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
    Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.